Breaking the vape habit: Challenges faced by young adult users

A randomized clinical trial explored the characteristics of young adult exclusive e-cigarette users seeking treatment, revealing high dependence levels, significant behavioral health concerns, and common usage of nicotine replacement therapies. Findings underscore the need for tailored cessation strategies targeting young adults.

CEO Doug Drysdale Explains Cybin Patent Approvals

The Dales Report is back with another Psychedelic Exclusive. Today we welcome Cybin CEO Doug Drysdale to the mic. Cybin is a clinical-stage biopharmaceutical company

October 27, 2023

Immutep picks up more funds for LAG-3 oncology and autoimmune studies

Immutep has raised about $53 million to bankroll its LAG-3 drugs across oncology and autoimmune diseases, giving it a cash runway to the first quarter

June 29, 2023

UQ and AbGenics partner to develop new drugs against antimicrobial resistance

UQ researchers have been awarded almost $1 million through the Australia-India Strategic Research Fund (AISRF) to combat the threat of antimicrobial resistance to human health.

July 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.